General
In April 2019, the Food and Drug Administration (FDA) issued a safety communication requiring opioid labeling changes to guide prescribers and patients on gradual, individualized tapering. The change was made after reports of serious harm in patients physically dependent on opioid pain medicines suddenly having the medicines discontinued or the dose rapidly decreased. Discontinuing or rapidly decreasing dose in dependent patients can cause serious withdrawal symptoms, uncontrolled pain, psychological distress and suicide. Providers are now…
Subscribe to the blog